We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » PATENT LAW HELPS FDA DETERMINE GENERICS 180-DAY EXCLUSIVITY
PATENT LAW HELPS FDA DETERMINE GENERICS 180-DAY EXCLUSIVITY
January 16, 2004
Patent reforms in the recently enacted Medicare drug benefit should help the FDA make decisions that will withstand legal challenges as brand firms fight vigorously to protect their products, and generics compete for billions of dollars worth of drugs going off patent.